Table 1. Demographic and clinical features in patients with and without sessile gastric polyps.
| Total patients n = 80 (%) | Patients with gastric neoplasm N = 19 (24 %) (%) | Patients without gastric neoplasm N = 61 (76 %) (%) | P value | |
| Age (std dev) | 48 (1.5) | 53.6 (3.1) | 46.2 (1.7) | 0.03 |
| Male | 56 (70) | 14 (73.7) | 42 (68.9) | 0.69 |
| APC pathogenic variant * | 45 (256.3) | 10 (52.6) | 35 (57.4) | 0.47 |
| Family history of FAP | 48 (60) | 12 (63.2) | 36 (59) | 0.60 |
| Family history of GC | 7 (8.8) | 4 (21.1) | 3 (4.9) | 0.05 |
| Other cancer | 0.28 | |||
| Thyroid carcinoma | 1 (1.3) | 0 (0) | 1 (1.6) | |
| Renal cell cancer | 1 (1.3) | 0 (0) | 1 (1.6) | |
| Ampullary carcinoma | 2 (2.5) | 0 (0) | 2 (3.3) | 0.99 |
| Colon adenocarcinoma | 11 (13.8) | 4 (21.1) | 7 (11.5) | 0.28 |
| Barrett’s esophagus | 1 (1.3) | 1 (5.3) | 0 (0) | 0.28 |
| Any tobacco use | 14 (17.5) | 3 (15.8) | 11 (18) | 0.99 |
| Any alcohol use | 24 (30) | 5 (26.3) | 19 (31.1) | 0.78 |
| PPI | 48 (60) | 15 (78.9) | 33 (54.1) | 0.06 |
| H 2 | 8 (10) | 2 (10.5) | 6 (9.8) | 0.99 |
| NSAID | 20 (25) | 8 (42.1) | 12 (19.7) | 0.07 |
| Sulindac | 18 (22.5) | 4 (21.1) | 14 (23) | 0.99 |
| Upper GI surgery | 11 (13.8) | 3 (15.9) | 7 (11.5) | 0.44 |
| Pylorus-preserving duodenectomy | 6 (7.5) | 1 (5.3) | 5 (8.2) | |
| Whipple | 1 (1.3) | 1 (5.3) | 0 (0) | |
| Bilroth I | 1 (1.3) | 0 (0) | 1 (1.6) | |
| Bilroth II | 2 (2.5) | 1 (5.3) | 1 (1.6) | |
| Partial duodenectomy | 1 (1.3) | 0 (0) | 1 (1.6) | |
| Colon surgery (IPAA, IRA, EI) | 70 (87.5) | 53 (86.9) | 17 (89.5) | 0.99 |
FAP, familial adenomatous polyposis; GC, gastric cancer; PPI, proton pump inhibitor; NSAID, nonsteroidal anti-inflammatory drug; GI, gastrointestinal; IPAA, ileal pouch-anal anastomosis; IRA, ileorectal anastomosis; EI, endo ileostomy .
*
Only if data available on pathogenic variant in individual.